Photo of Dr Thomas Fox

Dr Thomas Fox

Email:

Location:

  • University College Hospital

GMC/GDC number:

7082631

Professional background

Dr Thomas Fox is an honorary consultant haematologist at UCLH with a specialist interest in allogeneic haematopoietic stem cell transplantation, gene and cellular therapy. He graduated from Bristol University Medical School in 2010 and then completed his clinical and academic training on the North Central London rotation. He completed a PhD in molecular and cellular immunology at UCL. He provides a regular bone marrow transplant clinic and conducts research on gene editing and gene therapy at UCL. 
 

Specialties

Research interests

Stem cell transplantation
Gene editing 
Gene therapy
 

Publications

  1. Fox TA, Bueren J, Candotti F, Fischer A, Aiuti A, Lankester, A, The AGORA Initiative, Booth C. (2023) Access to gene therapy for rare diseases when commercialization is not fit for purpose. Nat Med 29, 518-519.
  2. Fox TA, Houghton B, Petersone L, Edner NM, Preham O, Waters E, Hinze C, Williams C, McKenna A, Pesenacker AM, Genovese P, Walker LSK, Burns SO, Sansom DM, Booth C, Morris EC. (2022) Therapeutic gene editing of T cells corrects CTLA4 insufficiency. Sci Transl Med 14 (668) doi: 10.1126/scitranslmed.abn5811.
  3. Cheminant M, Fox TA , Alligon M, Bouaziz O, Jais JP, Fieschi C, Guffroy A, Blanche S, Moshous D, Neven B, Comont T, Nouar D, Goujard C, Siproudhis L, Daveni M, Schleinitz N, Servettaz A, Luca L, Perlat A, Sylvain H, Fanny F, Cougoul P, Nunes C, Gomes C, Rohrlich PS, Marçais A, Barlogis V, Viallard JF, Malphettes M, Chakraverty R, Hermine O, Fischer A, Burns SO, Mahlaoui N, Morris EC, Suarez F. (2022) Allogeneic stem cell transplantation compared to conservative management in adults with primary immunodeficiency disorders and life-threatening complications: an international retrospective matched pairs analysis. Blood 141 (1): 60-71 DOI: 10.1182/blood.2022015482.
  4. Fox TA, Kirkwood AA, Enfield L, O’Reilly M, Arulogun S, D’Sa S, O’Nions J, Kavi J, Vistaras E, Townsend W, Burns SO, Gohil SH, Cwynarski K, Thomson KJ, Noursadeghi M, Heyderman RS, Rampling T, Ardeshna KM, McCoy LE, Morris EC. (2021) Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies. Br J Haematol 195 (5), 706-709.
  5. Fox TA, Booth C (2021) Gene therapy for primary immunodeficiencies. B J Haematol 193 (6): 1044-1059. doi:10.1111/bjh.17269.
  6. Fox TA, Chakraverty R, Burns S, Carpenter B, Thomson K, Lowe D, Fielding AK, Kottaridis P, Uttenthal B, Bigley V, Buckland M, Grandage V, Denovan S, Grace S, Dahlstrom J, Workman S, Symes A, Mackinnon S, Hough RE, Morris EC. (2018) Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency. Blood; 131 (8): 917-931.